Drug intelligence / Profile preview

allogeneic pancreatic islet cells

Development stage: Phase 2
Lead developer: Lorenzo Piemonti
Modality: Cell Therapies
Administration: Intra-omental, Intrahepatic

Overview

Allogeneic pancreatic islet cells are a biologic cell therapy consisting of purified clusters of endocrine cells (islets of Langerhans) derived from a donor pancreas. In the context of the ITA-OMEN trial led by Lorenzo Piemonti at Ospedale San Raffaele, these cells are being investigated for transplantation into the omentum as an alternative to the standard intrahepatic portal vein delivery. The primary goal is to restore endogenous insulin production and glycemic control in patients with type 1 diabetes mellitus who experience severe hypoglycemic unawareness or metabolic instability. The procedure requires a concomitant immunosuppressive regimen to prevent graft rejection.

Other names: allogeneic islet cellsislet transplantation

Beyond the preview

Go deeper on allogeneic pancreatic islet cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allogeneic pancreatic islet cells.